Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

计划入组 65 人 · 首次发布于 2022 年 3 月 14 日

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

计划入组 24 人 · 首次发布于 2023 年 1 月 18 日

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

计划入组 110 人 · 首次发布于 2023 年 11 月 7 日

Lutetium Lu-177(Lutathera, Lumark, EndolucinBeta, Lutetium (177Lu) chloride Billev (previously Illuzyce))

Lu

Lutetium Lu 177 dotatate(Lutathera)

C₆₅H₈₇LuN₁₄O₁₉S₂

Lutetium-177 oxodotreotide (Curium Pharma)

Laureate Institute for Brain Research

United States

Aveta Biomics, Inc.

United States

Selcuk University

Turkey

Curium Knocks Out Novartis Cancer Drug Patents in Generics Fight

Lantheus Receives FDA Tentative Approval for First Generic Version of LUTATHERA for Neuroendocrine Tumors

FDA Approves Curium's Bexlutry, First Generic Radioligand, Challenging Lutathera's GEP-NET Monopoly